MUFG
Mitsubishi UFJ Capital Co., Ltd.
MENUCLOSE
Text Size
  • S
  • M
  • L

OiDE® Fund

The OiDE Fund helps to nurture promising research findings and outcomes, typically from the Japanese university sector, into groundbreaking basic technologies for drug discovery from the perspective of pharmaceutical companies.

< Principal features >

  1. 1.Academic research outcomes are nurtured to the stage at which they are commercial prospects from the perspective of pharmaceutical companies.
  2. 2.A fully funded start-up is established when promising research outcomes are evident, whereupon full support is provided by Daiichi Sankyo regarding R&D, and by MUCAP regarding management.
  3. 3.If certain requirements are satisfied, Daiichi Sankyo may purchase shares in or intellectual property of the start-up based on predetermined pricing and conditions.

OiDE Fund Compared with Ordinary Fund

Scheme Figure
Name OiDE Fund Investment Limited Partnership
Open innovation for the Development of Emerging technologies
Objective To take promising research findings, typically from the Japanese university sector, before they are commercialized, and nurture them into groundbreaking basic technologies for drug discovery from the perspective of pharmaceutical companies.
Investment targets (1)Eligibility
Primarily start-ups newly established in Japan on the basis of research outcomes of Japanese universities, etc.
(2)Research outcomes
Basic technologies for drug discovery relating to nucleic acids, next-generation antibodies, peptides, drug delivery systems, vaccines, regenerative medicines, and cell therapies.
(3)Developmental stage
Stage at which the concepts as basic technologies for drug discovery have not been achieved or disease mechanisms not yet understood by means of nonclinical testing.
General partner Mitsubishi UFJ Capital
Investors Daiichi-Sankyo, Organization for Small and Medium Enterprises and Regional Innovation, Mitsubishi UFJ Capital etc
Total amount 849 million yen
Established September 17 2013
Fund term 10 years